MEPOLIZUMAB

MEPOLIZUMAB (12007Y)

mepolizumab 100 mg/mL injection, 1 mL pen device
12007Y
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 7 DPMQ: $1,556.10 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (12021Q)

mepolizumab 100 mg/mL injection, 1 mL pen device
12021Q
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $1,556.10 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (12043W)

mepolizumab 100 mg/mL injection, 1 mL pen device
12043W
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $1,604.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (12051G)

mepolizumab 100 mg/mL injection, 1 mL pen device
12051G
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 7 DPMQ: $1,604.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (12052H)

mepolizumab 100 mg/mL injection, 1 mL pen device
12052H
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $1,604.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (12064Y)

mepolizumab 100 mg/mL injection, 1 mL pen device
12064Y
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $1,556.10 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (13237Q)

mepolizumab 100 mg/mL injection, 1 mL pen device
13237Q
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment phase: Initial treatment

Restriction

Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $1,556.10 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala

MEPOLIZUMAB (13242Y)

mepolizumab 100 mg/mL injection, 1 mL pen device
13242Y
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment phase: Initial treatment

Restriction

Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $1,604.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala